Pharmaceutical Manufacturing Market Report 2026

The pharmaceutical manufacturing market size has grown rapidly in recent years. It will grow from $572.33 billion in 2025 to $630.77 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to expansion of global drug demand, growth in chronic disease prevalence, increasing investments in manufacturing capacity, advancement of formulation technologies, strengthening of regulatory quality standards.

The pharmaceutical manufacturing market size is expected to see strong growth in the next few years. It will grow to $923.47 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing investments in smart manufacturing facilities, rising adoption of advanced biologics production, expansion of personalized medicine manufacturing, growing focus on cost-efficient production models, increasing integration of digital quality management systems. Major trends in the forecast period include increasing adoption of continuous manufacturing technologies, rising focus on biologics and biosimilars production, expansion of advanced quality control systems, growing integration of automation and robotics, enhanced emphasis on regulatory compliance.

The growing prevalence of chronic diseases is expected to drive the expansion of the pharmaceutical manufacturing market in the coming years. Chronic diseases are long-term health conditions that generally progress gradually and last for a year or longer, often requiring continuous medical care or restricting everyday activities. The rising incidence of chronic illnesses is linked to factors such as increased life expectancy, sedentary lifestyles, and unhealthy dietary patterns, which together increase the need for sustained healthcare solutions and preventive interventions. Pharmaceutical manufacturing supports the management of chronic diseases by ensuring a reliable supply of essential medicines, enabling innovation in drug development, and addressing the rising demand for effective long-term treatment options. For instance, in September 2024, according to the National Health Service, a UK-based government department, around 11% of adults aged 35 and above were affected by advanced chronic kidney disease, with both prevalence and severity increasing with age. Nearly 48% of individuals aged 75 and older had some form of the disease, and 36% were experiencing more advanced stages. Therefore, the rising burden of chronic diseases is contributing to the growth of the pharmaceutical manufacturing market.

Major companies operating in the pharmaceutical manufacturing market are concentrating on advancing production capabilities through automation and technological innovation, such as the development of fully automated radioligand therapy (RLT) manufacturing facilities. These automated facilities use sophisticated technologies to optimize and streamline the production of radioligand therapies, ensuring consistent quality, efficiency, and scalability. For example, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration for the production of Pluvicto at a state-of-the-art RLT manufacturing facility in Indianapolis. This facility is expected to significantly expand production capacity for Novartis’ radioligand therapy medicines, including Pluvicto and Lutathera. The expansion aligns with the company’s broader strategy to address increasing global demand for targeted cancer therapies and improve patient access worldwide.

In December 2024, Novo Holdings A/S, a Denmark-based asset management company, acquired Catalent for $16.5 billion. Through this acquisition, Novo Holdings aims to strengthen its presence in the life sciences sector by leveraging Catalent’s expertise in drug development, pharmaceutical manufacturing, and clinical supply management. This strategic move is intended to accelerate growth, improve patient outcomes, and generate long-term value across the pharmaceutical and biotechnology industries. Catalent Inc. is a US-based company that provides pharmaceutical manufacturing services.

Major companies operating in the pharmaceutical manufacturing market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Inc., Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Lonza Group AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Cipla Limited, Samsung Biologics, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Lupin Limited, Jubilant Pharmova Limited.

North America was the largest region in the pharmaceutical manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pharmaceutical manufacturing market by increasing costs of imported active pharmaceutical ingredient processing equipment, reactors, automation systems, packaging machinery, and quality testing instruments. Manufacturing facilities in North America and Europe are most affected due to reliance on imported high-end equipment, while Asia-Pacific faces cost pressures on export-oriented production lines. These tariffs are increasing capital expenditure and influencing site expansion decisions. At the same time, they are encouraging domestic equipment manufacturing, regional supply chain localization, and investments in advanced manufacturing capabilities.

The pharmaceutical manufacturing market research report is one of a series of new reports that provides pharmaceutical manufacturing market statistics, including pharmaceutical manufacturing industry global market size, regional shares, competitors with a pharmaceutical manufacturing market share, detailed pharmaceutical manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical manufacturing industry. This pharmaceutical manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical manufacturing is the large-scale industrial process of developing, producing, and packaging medicines and medical products using chemical synthesis, biological processing, and the formulation of active and inactive ingredients. These activities are conducted under strict regulatory and quality control standards to ensure drug safety, efficacy, consistency, and compliance for human and veterinary use across global healthcare systems.

The primary molecule types in pharmaceutical manufacturing include biologics and biosimilars, as well as conventional drugs. Tablets are solid, flat dosage forms that contain a specific amount of active pharmaceutical ingredients. Pharmaceutical formulations encompass tablets, capsules, injectables, sprays, suspensions, powders, and others, which are administered through routes such as oral, topical, parenteral, inhalation, and additional methods. These products address a wide range of therapeutic areas, including cardiovascular diseases, pain management, diabetes, cancer, respiratory diseases, and others, and are distributed through both retail and non-retail sales channels.

The pharmaceutical manufacturing market consists of revenues earned by entities by providing services such as contract manufacturing, formulation development, quality control and testing, and packaging and labeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical manufacturing market also includes sales of syrups, patch formulations, biologics, and antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.